Metraipolis › archive › dc_eeaa09d37c45
Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site — Europe PMC PMID:36548304
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/36548304
- DOI
- 10.1371/journal.ppat.1011065
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-08T17:14:03.666Z
- SHA-256 of the archived text
a65edcfd23e3aabc4500471c4d685a3c6f1a591fe6c56b6430858972115dfb2c- Stable URL of this page
https://metraipolis.com/documento/dc_eeaa09d37c45
How to cite
Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site — Europe PMC PMID:36548304 — Europe PMC (en), https://europepmc.org/article/MED/36548304 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_eeaa09d37c45 (Metraipolis archive dc_eeaa09d37c45, sha256 a65edcfd23e3aabc4500471c4d685a3c6f1a591fe6c56b6430858972115dfb2c)
BibTeX
@misc{dceeaa09d37c45,
title = {Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site — Europe PMC PMID:36548304},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/36548304},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_eeaa09d37c45; sha256 a65edcfd23e3aabc4500471c4d685a3c6f1a591fe6c56b6430858972115dfb2c},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36548304. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has made it clear that combating coronavirus outbreaks benefits from a combination of vaccines and therapeutics. A promising drug target common to all coronaviruses-including SARS-CoV, MERS-CoV, and SARS-CoV-2-is the papain-like protease (PLpro). PLpro cleaves part of the viral replicase polyproteins into non-structural protein subunits, which are essential to the viral replication cycle. Additionally, PLpro can cleave both ubiquitin and the ubiquitin-like protein ISG15 from host cell substrates as a mechanism to evade innate immune responses during infection. These roles make PLpro an attractive antiviral drug target. Here we demonstrate that ubiquitin variants (UbVs) can be selected from a phage-displayed library and used to specifically and potently block SARS-CoV-2 PLpro activity. A crystal structure of SARS-CoV-2 PLpro in complex with a representative UbV reveals a dimeric UbV bound to PLpro at a site distal to the catalytic site. Yet, the UbV inhibits the essential cleavage activities of the protease in vitro and in cells, and it reduces viral replication in cell culture by almost five orders of magnitude. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS pathogens, 2022 (prima pubblicazione 2022-12-22). Identificativi: PMID 36548304 · PMCID PMC9822107 · DOI 10.1371/journal.ppat.1011065. Descrittori MeSH principali: Ubiquitin; COVID-19. Pagina: https://europepmc.org/article/MED/36548304 — https://doi.org/10.1371/journal.ppat.1011065. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-08T16:16:44.882Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.